trending Market Intelligence /marketintelligence/en/news-insights/trending/5SBK74hGo34Zhvv03KpAIw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Designations for Alnylam Pharmaceuticals, Provention Bio

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Designations for Alnylam Pharmaceuticals, Provention Bio

Approvals and designations made by the U.S. Food and Drug Administration for the week ended Aug. 9.

Complete response letters

* Kala Pharmaceuticals Inc.'s KPI-121 0.25% therapy to treat symptoms of dry eye disease.

Extended review

* Intra-Cellular Therapies Inc.'s lumateperone for schizophrenia. The FDA classified the New York-based company's planned submission of additional information as a major amendment to its application.

* Avadel Pharmaceuticals PLC's injectable hospital product candidate AV001 for an undisclosed indication. Dublin-based Avadel said it submitted additional information requested by the FDA which was considered by the regulator as a major amendment to the company's application.

SNL ImageFDA headquarters in Silver Spring, Md.
Source: Associated Press

Priority review

* Alnylam Pharmaceuticals Inc.'s givosiran for acute hepatic porphyria. The FDA said efficacy data from an additional clinical trial will be needed to support resubmission of the application.

Breakthrough therapy

* Provention Bio Inc.'s PRV-031 for preventing and delaying type 1 diabetes.